{"id":"delayed-administration-of-convalescent-plasma","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Transfusion-associated circulatory overload (TACO)"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Convalescent plasma is collected from patients who have recovered from infection and contains pathogen-specific antibodies and other immune mediators. When administered to acutely ill patients, these antibodies provide immediate passive immunity to neutralize the pathogen and modulate the immune response. Delayed administration refers to timing the infusion after initial disease progression rather than early in infection.","oneSentence":"Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:57.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (delayed administration in hospitalized patients)"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04374565","phase":"PHASE2","title":"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-05-05","conditions":"Corona Virus Infection, SARS-CoV 2, SARS Pneumonia","enrollment":29},{"nctId":"NCT04458363","phase":"EARLY_PHASE1","title":"Convalescent Plasma in Pediatric COVID-19","status":"COMPLETED","sponsor":"Emory University","startDate":"2020-07-04","conditions":"COVID","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Delayed administration of convalescent plasma","genericName":"Delayed administration of convalescent plasma","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Biologic","firstApprovalDate":"","aiSummary":"Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease. Used for COVID-19 (delayed administration in hospitalized patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}